News Oral insulin could still be a reality, says Novo Nordisk Last October Novo Nordisk announced that it had shelved plans to bring the world’s first oral insulin to market .
News Novo hopes data will boost new insulin in US and Germany Novo Nordisk hopes that new data supporting the cardiovascular and glycaemic safety of its Tresiba long-acting insulin will prove a game-changer in the US.
Views & Analysis ADA preview: cardio data in diabetes, drug costs and healthc... Invokana data could suggest cardio benefit for SGLT2 class.
Views & Analysis Novo Nordisk: survival of the fittest applies in diabetes an... Diabetes specialist Novo Nordisk is feeling the heat from increasingly price conscious US payers.
News Novo hopes hypoglycaemia data will boost Tresiba Lower severe hypo risk compared with Lantus - but no cardiac benefit.
News AZ’s Bydureon disappoints in diabetes outcomes trial Results give advantage to Boehringer/Lilly's Jardiance.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
